Hot topics

IRE supplies a first commercial batch of LEU-based Mo-99
04-30-2020

IRE supplies a first commercial batch of LEU-based Mo-99

Fleurus, Belgium – April 30th, 2020 - The Institute for radioelements (IRE), one of the leaders in the production of Molybdenum-99 (Mo-99), the most widely used radio-isotope in nuclear medicine for diagnosis, announced today that the company produced its first commercial Mo-99 Low Enriched Uranium (LEU) batch for the US market.

Read more
Communication about Covid-19
03-16-2020

Communication about Covid-19

Message from the Management of IRE- IRE ELIT
As COVID-19 continues to spread, our thoughts go out to those who have been infected or impacted. We hope that you, your family, friends and colleagues are safe and well, and are taking the necessary precautions to keep it that way.

Following the Belgium government's decision of strict confinement from March 18th, IRE – IRE ELiT is considered a requisitionable and essential company ( = vital interests category), so we are adapting our measures and our business continuity plan to comply with instructions, preserving the health of our staff and their families while ensuring that our clients and patients continue benefiting worldwide from our isotopes for diagnostics and therapy.

Read more
- Press Release - IRE and SCK CEN Partnership on lutetium-177 production: a ray of hope for prostate cancer treatment
02-13-2020

- Press Release - IRE and SCK CEN Partnership on lutetium-177 production: a ray of hope for prostate cancer treatment

IRE (Institut National des Radioéléments) and SCK CEN are joining forces to benefit medicine. Both organisations specialised in the research, development and production of medical radioisotopes, signed a public-public partnership whose initial aim is to produce lutetium-177 (Lu-177). This medical radioisotope gives a ray of hope to treat prostate cancer, which causes around 90,000 deaths per year in Europe.

Read more

Last news

Events

Archives

IRE Elit - Environement and lifescience Technology